Skip to main content

Specimen Collection Manual and Test Catalog

  or
  or
  or

FISH, HES/LEUKEMIA, 4Q12 REARRANGEMENT (FIP1L1-PDGFRA)

Geisinger Epic Procedure Code:  LAB1250    Geisinger Epic ID:  52925

SPECIMEN COLLECTION
Specimen type: 

Bone marrow or whole blood (preferred). Formalin-fixed, paraffin-embedded block and fresh tumor tissue samples are also acceptable.


Preferred collection container: 
Alternate collection container: 
Tissue culture transport media
Paraffin-embedded block
Specimen required: 

3 mL bone marrow (minimum 1 mL) or 5 mL whole blood (minimum 3 mL) or 5x5mm fresh tumor tissue collected in transport medium or formalin-fixed paraffin-embedded tissue block



SPECIMEN PROCESSING
Transport temperature: 

Room temperature.


Specimen stability: 

Specimen viability decreases during transit. Send specimen to testing lab for viability determination. Do not freeze. Do not reject.



TEST DETAILS
Additional information: 

This test was developed and its analytical performance characteristics have been determined by Quest Diagnostics. It has not been cleared or approved by the U.S. Food and Drug Administration. This assay has been validated pursuant to the CLIA regulations and is used for clinical purposes


CPT code(s):  88275, 88271 x3
Note: The billing party has sole responsibility for CPT coding.  Any questions regarding coding should be directed to the payer being billed.
The CPT codes provided by GML are based on AMA guidelines and are for informational purposes only.

Test includes: 

Note: 100-200 interphase nuclei are examined microscopically for the rearrangements of 4q12. If results are not possible, the test order may be canceled and replaced with a Cytogenetics Communication.


Methodology: 
Fluorescence In Situ Hybridization (FISH)
Synonyms: 

Quest test code 16837, FISH HES


Clinical significance: 

FIP1L1-PDGFRa fusion (rearrangement of 4q12; interstitial deletion of CHIC2 region) is observed in diverse eosinophilia-associated hematologic disorders. The cases with FIP1L1-PDGFRa fusion show an excellent response to the tyrosine kinase inhibitor imatinib mesylate (Metzgeroth et al, 2007)


Review Date:  12/11/2024

Performing Locations